HighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes

Reuters

2025/10/31

HighTide <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes

HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, SYMPHONY-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two Fast Track designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579107493"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579107493\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579107493?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579107493","market":"us","top_or_hot":-1,"title":"HighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HighTide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, <a href=\"https://laohu8.com/S/SIHL.UK\">SYMPHONY</a>-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-31 08:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HighTide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, <a href=\"https://laohu8.com/S/SIHL.UK\">SYMPHONY</a>-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL1zytV2:1","article_id":"2579107493","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579107493","pubTimestamp":1761869164,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, SYMPHONY-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two Fast Track designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.Disclaimer: This news brief was created by Public Technologies  using generative arti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02511":"君圣泰医药-B"},"translate_title":"HighTide Therapeutics报告HTD1801治疗2型糖尿病52周III期结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":0.9},"content_text":"HighTide Therapeutics Reports Positive 52-Week Phase III Results for HTD1801 in Type 2 Diabetes\n    \n\n        HighTide Therapeutics, Inc. has announced positive 52-week efficacy and safety results from the open-label extension phases of two Phase III trials, SYMPHONY-1 and SYMPHONY-2, evaluating its lead asset HTD1801 in patients with type 2 diabetes mellitus. The data demonstrate that HTD1801, a first-in-class anti-inflammatory metabolic modulator, showed durable efficacy and safety over 52 weeks. The results highlight the drug's potential to address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes mellitus. These findings have already been presented by the company. HTD1801 has also received two Fast Track designations and one Orphan Drug designation from the US FDA and has been selected for China's National Major Science and Technology Project for Significant New Drug Development. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}